MeSH term
Frequency | Condition_Probility | Animals | 66 | 0.0 |
Biological Markers | 2 | 0.0 |
Humans | 129 | 0.0 |
Bone Morphogenetic Proteins/pharmacology | 2 | 6.0 |
Cell Differentiation | 5 | 0.0 |
Cell Line | 36 | 0.0 |
DNA-Binding Proteins/*physiology | 3 | 0.0 |
Mice | 31 | 0.0 |
*Proteins | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 106 | 0.0 |
Trans-Activators/*physiology | 3 | 1.0 |
*Transforming Growth Factor beta | 7 | 4.0 |
Male | 18 | 0.0 |
Rats | 8 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 38 | 0.0 |
DNA-Binding Proteins/metabolism | 8 | 0.0 |
Phosphorylation | 24 | 0.0 |
Signal Transduction/*physiology | 18 | 1.0 |
Trans-Activators/metabolism | 8 | 0.0 |
Transforming Growth Factor beta/*physiology | 9 | 6.0 |
Activin Receptors, Type I/genetics/*metabolism | 2 | 40.0 |
Activin Receptors, Type II/genetics/metabolism | 2 | 100.0 |
Amino Acid Sequence | 9 | 0.0 |
CHO Cells | 4 | 0.0 |
Cells, Cultured | 27 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Gene Expression | 9 | 0.0 |
Genes, Reporter | 13 | 0.0 |
Hamsters | 4 | 0.0 |
Molecular Sequence Data | 12 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Receptors, Transforming Growth Factor beta/metabolism | 5 | 11.0 |
Transfection | 32 | 0.0 |
Adult | 11 | 0.0 |
Cell Division/physiology | 4 | 0.0 |
Female | 23 | 0.0 |
Frameshift Mutation | 2 | 0.0 |
Immunohistochemistry | 10 | 0.0 |
Middle Aged | 13 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Signal Transduction/physiology | 6 | 0.0 |
Transforming Growth Factor beta/*antagonists & inhibitors/physiology | 3 | 60.0 |
Tumor Cells, Cultured | 25 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, SCID | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Signal Transduction/*immunology | 2 | 0.0 |
Blotting, Western | 9 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Phosphorylation/drug effects | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Transforming Growth Factor beta/pharmacology | 3 | 0.0 |
DNA-Binding Proteins/*genetics/*physiology | 2 | 5.0 |
Genetic Vectors | 5 | 0.0 |
Models, Biological | 6 | 0.0 |
Phenotype | 2 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Signal Transduction | 32 | 0.0 |
Trans-Activators/*genetics/*physiology | 2 | 16.0 |
Transforming Growth Factor beta/physiology | 2 | 2.0 |
Cell Division/drug effects | 6 | 0.0 |
DNA-Binding Proteins/*metabolism | 20 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Trans-Activators/*metabolism | 21 | 2.0 |
Transforming Growth Factor beta/antagonists & | 2 | 33.0 |
Transforming Growth Factor beta/*pharmacology | 17 | 4.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 3 | 0.0 |
NF-kappa B/metabolism | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Binding Sites | 7 | 0.0 |
Blotting, Northern | 8 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Fibroblasts/*metabolism | 3 | 1.0 |
Genes, Dominant | 5 | 0.0 |
Immunoblotting | 8 | 0.0 |
Mutation | 9 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Plasmids/metabolism | 4 | 0.0 |
Promoter Regions (Genetics) | 14 | 0.0 |
Transcription, Genetic | 11 | 0.0 |
Transforming Growth Factor beta/*metabolism | 21 | 9.0 |
Activin Receptors | 3 | 16.0 |
Apoptosis | 3 | 0.0 |
Bone Morphogenetic Proteins/*metabolism | 4 | 9.0 |
COS Cells | 11 | 0.0 |
Cell Division | 7 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 15 | 1.0 |
Luciferases/genetics | 5 | 1.0 |
Phosphoproteins/genetics/*metabolism | 2 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 4 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 4 | 0.0 |
*Signal Transduction | 14 | 0.0 |
Trans-Activators/genetics/*metabolism | 15 | 4.0 |
*Apoptosis | 3 | 0.0 |
DNA Fragmentation | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Protein Binding | 13 | 0.0 |
Time Factors | 11 | 0.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Butadienes/pharmacology | 2 | 3.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Furin | 2 | 4.0 |
Luciferases/metabolism | 5 | 0.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 2 | 1.0 |
Nitriles/pharmacology | 2 | 1.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
RNA, Messenger/analysis | 9 | 0.0 |
Base Sequence | 11 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 8 | 0.0 |
Gene Frequency | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Trans-Activators/*genetics | 7 | 2.0 |
Chromosomes, Human, Pair 18/*genetics | 2 | 2.0 |
Colorectal Neoplasms/*genetics | 2 | 0.0 |
Signal Transduction/genetics | 4 | 1.0 |
*Gene Expression Regulation | 6 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Gene Expression Regulation | 7 | 0.0 |
RNA, Messenger/drug effects/genetics/metabolism | 3 | 3.0 |
Transforming Growth Factor beta/*antagonists & inhibitors | 4 | 30.0 |
*Activin Receptors, Type I | 2 | 8.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Epithelial Cells/cytology/physiology | 2 | 6.0 |
Ligases/*metabolism | 2 | 2.0 |
Mink | 4 | 6.0 |
Sequence Alignment | 2 | 0.0 |
Trans-Activators/chemistry/*metabolism | 2 | 3.0 |
*Ubiquitin-Protein Ligases | 5 | 0.0 |
Cyclins/genetics | 2 | 1.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Bone Morphogenetic Proteins/*physiology | 2 | 9.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
*Cell Cycle Proteins | 2 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 4 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Trans-Activators/genetics/metabolism | 5 | 2.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
Transforming Growth Factor beta/*metabolism/pharmacology | 6 | 24.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Signal Transduction/drug effects/*physiology | 3 | 1.0 |
3T3 Cells | 2 | 0.0 |
DNA/metabolism | 5 | 0.0 |
Pancreatic Neoplasms/*metabolism/pathology | 2 | 4.0 |
Prognosis | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Drug Synergism | 4 | 0.0 |
Transforming Growth Factor beta/metabolism | 6 | 3.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Receptors, Transforming Growth Factor beta/*metabolism | 2 | 7.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Mesoderm/metabolism | 2 | 2.0 |
RNA, Messenger/metabolism | 11 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Fibroblasts/cytology/*metabolism | 2 | 5.0 |
Skin/cytology | 2 | 1.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Gene Expression Regulation/drug effects | 5 | 0.0 |
Trans-Activators/*genetics/metabolism | 2 | 1.0 |
DNA Primers | 4 | 0.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Trans-Activators/genetics | 4 | 1.0 |
Activins | 4 | 5.0 |
DNA-Binding Proteins/genetics/*physiology | 2 | 0.0 |
Trans-Activators/genetics/*physiology | 2 | 2.0 |
Precipitin Tests | 5 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
DNA-Binding Proteins/metabolism/*physiology | 3 | 2.0 |
Receptors, Transforming Growth Factor beta/physiology | 3 | 30.0 |
Trans-Activators/metabolism/*physiology | 3 | 5.0 |
Two-Hybrid System Techniques | 3 | 0.0 |
Ubiquitin/metabolism | 4 | 1.0 |
Aged | 7 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Comparative Study | 2 | 0.0 |
Cyclins/metabolism | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 3 | 3.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Ligands | 2 | 0.0 |
Receptors, Transforming Growth Factor beta/*genetics | 3 | 6.0 |
DNA/genetics | 2 | 0.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Down-Regulation | 6 | 0.0 |
Fibrosis | 5 | 3.0 |
Trans-Activators/*genetics/*metabolism | 2 | 5.0 |
Ubiquitin/*metabolism | 2 | 1.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 2 | 1.0 |
Cell Line, Tumor | 6 | 0.0 |
DNA-Binding Proteins/biosynthesis/genetics/*physiology | 2 | 5.0 |
Trans-Activators/biosynthesis/genetics/*physiology | 2 | 13.0 |
Lung | 2 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
*Trans-Activators | 5 | 0.0 |
Cattle | 2 | 0.0 |
Endothelium, Vascular/cytology/*metabolism | 2 | 1.0 |
*Transcription, Genetic | 3 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
RNA, Small Interfering/metabolism | 2 | 1.0 |
Up-Regulation | 8 | 0.0 |
Chromatin/metabolism | 2 | 0.0 |
Hela Cells | 4 | 0.0 |
RNA Interference | 2 | 0.0 |
Xenopus | 2 | 0.0 |
Umbilical Veins/cytology | 2 | 0.0 |
Transforming Growth Factor beta/metabolism/*physiology | 2 | 33.0 |
Actins/metabolism | 3 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
DNA-Binding Proteins/*analysis | 2 | 3.0 |
Neoplasm Staging | 2 | 0.0 |
Trans-Activators/*analysis | 2 | 8.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Subcellular Fractions/metabolism | 3 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
RNA/metabolism | 3 | 0.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 4 | 0.0 |
Cell Differentiation/physiology | 3 | 0.0 |
Collagen/*biosynthesis | 2 | 5.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Carcinoma/*metabolism | 2 | 2.0 |
Jurkat Cells | 2 | 0.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
English Abstract | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Fibroblasts/*physiology | 2 | 3.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors | 2 | 3.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Activin Receptors, Type I/genetics/metabolism | 2 | 28.0 |
Fibroblasts/cytology | 2 | 0.0 |
Gene Expression/physiology | 2 | 0.0 |
Activins/*metabolism | 2 | 25.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
